| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22042 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Is indicated for the adjuvant treatment of adults and adolescent (≥12 years) with stage IIB or IIC melanoma following complete resection. |
| Rapid review commissioned |
22/06/2022 |
| Rapid review completed |
14/07/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/07/2022 |
| Pre-submission consultation with Applicant |
15/11/2022 |
| Full submission received from Applicant |
27/07/2023 |
| Preliminary review sent to Applicant |
21/12/2023 |
| NCPE assessment re-commenced |
01/02/2024 |
| Factual accuracy sent to Applicant |
28/03/2024 |
| NCPE assessment re-commenced |
05/04/2024 |
